A Phase Ib/IIa Clinical Trial Evaluating the Safety, Tolerability, and Efficacy of GR1803 Injection in Subjects With Systemic Lupus Erythematosus
Latest Information Update: 27 Jan 2026
At a glance
- Drugs Velinotamig (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Genrix (Shanghai) Biopharmaceuticals
Most Recent Events
- 27 Jan 2026 New trial record